Profit Dependence on the BGM System Business
First written in FY2024. 2 of 5 entries say "Restated". Latest entry: 2026-05-13.
PHC Holdings moved to the "Worse" side of this theme in 2026, the same year as the typical company in this theme.
The whole theme swung hardest in 2017: 2 of 11 companies on the "Worse" side.
2 other companies' latest entry also says "Reframed".
- 2026-05-13ReframedEarnings
「The business achieved a substantial increase in profit as a result of improved profitability associated with the transfer of the CGM business and other factors.」
The risk disclosure regarding dependence on the BGM business for profit was updated to reflect the completion of the transfer of the CGM distribution business and the resulting improvement in profitability. - FY2026-H1ReframedAnnual report
「The company resolved at a Board of Directors meeting to enter into a basic agreement, on 4 September 2025 Japan time, concerning the transfer to Senseonics of the sales business for Eversense, a continuous glucose monitoring (CGM) system operated by the company's consolidated subsidiary ADCHD.」
The disclosure of profit dependence on the BGM business was supplemented with a basic agreement to transfer the CGM sales business to Senseonics, shifting the context toward a review of the business portfolio. - FY2025RestatedAnnual report
「Total segment profit for the fiscal year ended March 2025, before Other and adjustments and eliminations, was ¥30,409 million, of which segment profit from Diabetes Management was ¥13,888 million.」
The company continues to disclose the risk of profit dependence on Diabetes Management, including BGM. Profit was ¥13,888 million, down from the previous fiscal year, while the risks of developed-market contraction and failure to expand CGM remain. - FY2025-H1RestatedAnnual report
「The blood glucose monitoring system (BGM) business posted a slight decline in revenue. Growth in emerging markets and positive foreign exchange effects were offset by continued market contraction in developed markets such as Europe and the United States, a shift to lower-priced channels and the impact of the end of the US sales collaboration.」
The BGM business posted a slight decline in revenue due to the contraction of developed markets and other factors, and continued volatility in the BGM business's performance related to profit dependence was confirmed. - FY2024First statedAnnual report
「Total segment profit for the fiscal year ended March 2024, before Other and adjustments and eliminations, was ¥12,206 million, of which segment profit from Diabetes Management was ¥15,333 million.」
The company discloses the risk of declining profits if the BGM market contracts or CGM expansion falls short, given that Diabetes Management generates profit exceeding total segment profit.